A Preclinical Paradigm to Assess the Potential Risk and In Vivo Mechanism(s) Responsible for the Bradyarrhythmia Observed in Hepatitis-C Virus (HCV) Infected Patients Treated with Direct-Acting Antivirals (DAAs) and Amiodarone